UNSPSC 51413202: Cinepazide

This classification denotes a vasodilating agent with the molecular formula C22H31N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67Y4P5C84X, chemically known as 1-((1-pyrrolidinylcarbonyl)methyl)-4-(3,4,5-trimethoxycinnamoyl)piperazine but generally known as cinepazide, which bears US NIH Compound Identifier 2759. European Medicines Agency schedules Cinepazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06293MIG.

UNSPSC 51413202 Cinepazide is a Commodity code that covers pharmaceutical products for emergency medical use, specifically advanced life support medications supplied to municipal emergency response agencies. State and local governments buy these medications—including epinephrine injections, labetalol, adenosine, diltiazem, and related compounds—through sealed competitive bidding to stock fire rescue services and emergency medical programs. Issuing bodies under this code are primarily municipal purchasing departments acting on behalf of fire rescue and emergency medical services divisions. The City of Tampa's Purchasing Department has solicited these medications for Tampa Fire Rescue, indicating that mid-sized municipalities with established emergency response infrastructure are active buyers. Vendors must meet strict regulatory requirements including OSHA Safety Data Sheets compliance, nine-month minimum expiration dates at delivery, warranty against defects for one year, and rapid replenishment capabilities within ten calendar days of order.

The most recent documented activity under this code appears in Florida, specifically Hillsborough County. The City of Tampa Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00, offering a five percent bid discount for Small Local Business Enterprise (SLBE) participation capped at $10,000. The contract term runs one year from award with two optional one-year renewals and unilateral extension rights for up to three additional 30-day periods. This solicitation represents a relatively narrow opportunity set; the source provides no evidence of concurrent procurement activity under this code in other states or jurisdictions, suggesting either limited recent state and local demand or sparse reporting coverage for this specific pharmaceutical commodity.